Segmed, Inc.

📢 New Blog Series: Breaking Down FDA Guidance on Real-World Evidence (RWE) The evolving FDA guidelines on Real-World Data (RWD) and Real-World Evidence (RWE) are critical for healthcare professionals, researchers, and innovators alike. At Segmed, we're committed to helping the medical community leverage data for smarter, more informed decisions. That's why we're excited to launch a new blog series unpacking key FDA guidelines on RWE, EHRs, and medical claims data. Check out each blog to learn how these regulations can shape the future of healthcare innovation! 💡 FDA Guidance on RWE from EHRs and Medical Claims for Regulatory Decisions > https://hubs.li/Q02Q_M300 💡 FDA’s Guidance on RWE and RWD: Guidance Regarding Data Sources > https://hubs.li/Q02Q_KQl0 💡 FDA Guidelines for Leveraging RWD from EHRs and Medical Claims: Guidance Regarding Study Design Elements > https://hubs.li/Q02Q_hgN0 This series will break down complex regulatory frameworks, providing actionable insights for leveraging EHR and medical claims data. Dive in and stay informed about how RWD is transforming healthcare innovation! Join the conversation! Share your thoughts on how RWE and RWD are shaping the future of healthcare, and let us know how you’re leveraging these insights in your work! #RWE #RWD #HealthcareInnovation #FDA #EHR #Segmed #MedicalClaims #HealthTech

We’re excited that Jessica Baldridge, our Senior Director of Business Development, will be attending #HLTH2024 in Las Vegas! 🎉 If you’re attending too, this is a great opportunity to meet and chat about your imaging data needs. Reach out and schedule some time with her here: https://lnkd.in/eJ_up53V Let’s connect and explore how we can help you leverage imaging data for #AI and health innovation. 🏥💡 #hlth #hlthlasvegas #medicalimaging #data #imaging #healthtech #healthcare

NASCI 2024 just concluded, showing how the integration of real-world data, including imaging data, is essential for driving innovation in cardiovascular research. Our fit-for-purpose regulatory grade real-world imaging datasets (RWiD) and multimodal longitudinal datasets are tailored to meet the needs of pharmaceutical and biotech companies. These datasets have been instrumental in planning and optimizing clinical trials, ensuring the recruitment of suitable patients. Reach out to us at https://hubs.li/Q02RhfXy0 to know more about how our data sets and solutions have supported identification of suitable patient cohorts for treatment and streamline clinical trial planning. Let’s connect to discover how we can support your next big breakthrough in cardiology. #CardiovascularResearch #MedicalImaging #PharmaExcellence #NASCI2024 #Cardiology #Radiology #RWD #RWiD #RWE

🚀 The Segmed team recently had the privilege of attending the #BioTechX2024 in Philadelphia on September 17th and 18th. The conference provided us with the opportunity to engage in several sessions focused on real-world evidence, AI in drug discovery, and digital transformation. 💡 Here is what our team had to say about the conference: “BioTechX 2024 provided valuable insights into the integration of real-world data and advanced analytics in the biotech, pharmaceutical, and medical device industries. We had the opportunity to engage with key stakeholders to discuss how real-world imaging data can support their research and development efforts. The conference highlighted the increasing role of artificial intelligence in data interpretation and the importance of data standardization for research scalability. These discussions reinforced our commitment to delivering high-quality data that meets the evolving needs of our pharma and med device partners.” - said @Taylor Duguay, our Director of Clinical Development. We at Segmed are excited for the way forward and about the potential real-world imaging datasets (RWiD) will be playing in the R&D. Segmed provides tailored RWiD and multimodal longitudinal datasets that are instrumental in accelerating drug development, clinical trial design, and innovation for pharmaceutical and biotech companies. 📞 To learn more about our offerings and how it can support your drug development programs, contact us https://hubs.li/Q02Rj9xF0 #BioTechX2024 #BioTechXUSA #RealWorldEvidence #RWE #DigitalTransformation #RWiD #MedicalImaging #RWD #RealWorldData #AIinDrugDiscovery #ArtificialIntelligence #AI #PharmaInnovation #Biotech #ClinicalTrials #DataDrivenHealthcare #HealthTech #Pharmaceuticals #LifeSciences

#NASCI2024 has come to a close, showcasing the remarkable advancements in cardiovascular imaging and providing valuable insights into the field of cardiovascular disease. Real-world evidence and real-world imaging data are crucial for comprehending the effectiveness of treatments and patient outcomes in the cardiovascular domain. Segmed provides high-quality, regulatory-grade real-world imaging datasets (RWiD) and multimodal longitudinal datasets that are specifically designed to aid in biomarker discovery and patient identification for treatment in cardiovascular therapy. Connect with us at https://hubs.li/Q02Rh99M0 to learn how our data can support your research and development efforts in the cardiovascular space. #CardiovascularImaging #RWE #RWiD #CardiovascularDisease #PharmaceuticalResearch #MedicalImaging #HealthcareInnovation #ClinicalTrials

📢 New Blog Series: Breaking Down FDA Guidance on Real-World Evidence (RWE) The evolving FDA guidelines on Real-World Data (RWD) and Real-World Evidence (RWE) are critical for healthcare professionals, researchers, and innovators alike. At Segmed, we're committed to helping the medical community leverage data for smarter, more informed decisions. That's why we're excited to launch a new blog series unpacking key FDA guidelines on RWE, EHRs, and medical claims data. Check out each blog to learn how these regulations can shape the future of healthcare innovation! 💡 FDA Guidance on RWE from EHRs and Medical Claims for Regulatory Decisions > https://hubs.li/Q02Q_M300 💡 FDA’s Guidance on RWE and RWD: Guidance Regarding Data Sources > https://hubs.li/Q02Q_KQl0 💡 FDA Guidelines for Leveraging RWD from EHRs and Medical Claims: Guidance Regarding Study Design Elements > https://hubs.li/Q02Q_hgN0 This series will break down complex regulatory frameworks, providing actionable insights for leveraging EHR and medical claims data. Dive in and stay informed about how RWD is transforming healthcare innovation! Join the conversation! Share your thoughts on how RWE and RWD are shaping the future of healthcare, and let us know how you’re leveraging these insights in your work! #RWE #RWD #HealthcareInnovation #FDA #EHR #Segmed #MedicalClaims #HealthTech

This week, we're eagerly following the cutting-edge developments in cardiology imaging at the North American Society for Cardiovascular Imaging 2024. Join Martin Willemink, MD PhD FSCCT, our cofounder and CEO, at NASCI going through his journey from starting up on an idea to launching a company and understanding more about Segmed and its offerings. The session will be on Monday, September 23rd, at 9:30am. Segmed’s offerings support the advancement of cardiovascular research by providing high-quality, regulatory-grade real-world imaging datasets (RWiD) and multimodal longitudinal datasets. Our datasets offer the precision and insights essential for pharmaceutical companies to develop groundbreaking treatments and interventions in cardiology. Contact us https://hubs.li/Q02QDgwq0 to learn how our datasets can help improve the precision and early detection of cardiovascular conditions. #NASCI2024 #CardiovascularImaging #MedicalImaging #CT #MR #Radiology #Cardiology #RWE #RWD #RWiD #CardiovascularData #ClinicalTrials

Segmed is excited to be part of #NASCI2024, the North American Society for Cardiovascular Imaging's Annual Meeting! This prestigious global conference brings together leading experts in cardiovascular imaging and will take place in Boston, Massachusetts, starting this weekend. Our CEO, Martin Willemink, MD PhD FSCCT, will be presenting on “From Startup Idea to Launching a Successful Company” at a session moderated by Dr. Jacobo Kirsch, MD, MBA (Cleveland Clinic) and Dr. Pat Mergo (Mayo Clinic) on Monday, September 23, 2024, within the session Career Development. 🗓 Date: Monday, September 23, 2024 🎤 Presentation time: 10:15 AM - 10:30 AM Don’t miss this opportunity to hear about the journey that shaped Segmed from a startup to a leader in the health innovation space. Our CEO will share valuable insights on overcoming challenges, building momentum, and driving success in the dynamic world of health tech. We look forward to engaging with the best minds in the field and contributing to the discussions shaping the future of cardiovascular health. #NASCI2024 #CardiovascularImaging #MedicalImaging #CT #MR #Radiology #Cardiology #RWE #RWD #RWiD #CardiovascularData #ClinicalTrials

The NASCI 2024 serves as a platform to underscore the crucial role of medical imaging in propelling cardiovascular research forward, as experts from cardiology and radiology unite. Segmed is a global leader in providing fit-for-purpose, regulatory-grade RWiD and multimodal longitudinal datasets, essential for precise cardiovascular drug and interventional development, biomarker discovery, patient recruitment, as external control arm, real world evidence generation and algorithm development & validation. Explore how our data can accelerate your cardiovascular research and development. Contact us https://hubs.li/Q02QC_t40 #NASCI2024 #CardiovascularImaging #MedicalImaging #CT #MR #Radiology #Cardiology #RWE #RWD #RWiD #CardiovascularData #ClinicalTrials

🤔 Can AI-generated medical images revolutionize healthcare while protecting patient privacy? 📄 This Radiological Society of North America (RSNA) Radiology paper provides a nicely balanced review that explores the benefits of synthetic medical imaging data while highlighting its challenges and ethical considerations. Synthetic medical imaging data generated by AI models like GANs and diffusion models offers many potential applications in healthcare, including dataset enrichment, deidentification, intermodality translation, contrast synthesis, and radiologist training. While this technology can potentially address data scarcity and privacy issues in medical AI development, it faces significant challenges. These include generating realistic pathology, preventing identity leakage, managing high computational costs, etc. In addition, current regulatory frameworks like HIPAA and GDPR are insufficient to address the unique concerns posed by synthetic data. 🚧 I wanted to emphasize the "amplified-bias" challenge mentioned in the paper. What's visible is the easier part, as we can now create synthetic lesions that could convince expert radiologists. What’s challenging is what we cannot see: what hidden biases or erroneous features are we unwittingly perpetuating? This is something I highlight in my recent Radiology editorial. 👍 This is a good read for anyone working with synthetic data for medical imaging. 🔗 to the original paper and my editorial are in the first comment. #MedicalAI #SyntheticData #PatientPrivacy #radiology #RadiologyAI #GenAI